Kaiser Permanente Oakland M.C.(9.6 mi away)Contact
+102 other location
severe haemophilia a
recombinant factor viii
immune tolerance induction
The purpose of this study is to investigate safety, immunogenicity and hemostatic efficacy of
PEGylated recombinant FVIII (BAX 855) in previously untreated patients (PUPs) < 6 years of
age with severe hemophilia A (baseline FVIII level < 1%) and < 3 EDs to ADVATE, BAX 855 or
PEGylated Recombinant Factor VIII
Clinical Study Identifier
Baxalta now part of Shire
Last Modified on
2 August 2020
How clear was the trial content above?
Adding a note
Select a piece of text and start making personal notes.
If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.